ManufacturingINVESTAnnounced
HRV Pharma and Arene Lifesciences to jointly invest ₹50 crore in peptide facility
Hyderabad, Telangana7 Sept 2026
HRV Pharma has signed an agreement with Hyderabad-based Arene Lifesciences to jointly invest ₹50 crore in a dedicated synthetic peptide facility. Under the agreement, Arene will own the facility while HRV will underwrite capacity exclusively for its requirements and retain ownership of regulatory assets, product IP, and global commercialisation rights.
Why it matters
Dedicated peptide manufacturing capacity can enable HRV to supply regulated markets with greater reliability while keeping its model focused on owning IP and regulatory rights rather than plant ownership.
HRV PharmaArene Lifesciences